As some Danish hospitals begin introducing remifentanil for labour pain, a significant share of women giving birth in Denmark are foreign-born, yet detailed risk information on this powerful opioid remains largely unavailable in English and framed for surgical use, not childbirth.
According to TV 2 reporting, remifentanil is being introduced on some Danish labour wards as a patient-controlled painkiller. The drug is already authorised in Denmark as a hospital-only anaesthetic and intensive care opioid. Its formal product information warns of serious risks including respiratory depression, heart rhythm disturbances, and in the worst case death from overdose or poisoning. Those warnings apply to all uses of the drug, including in spontaneous-breathing patients outside the operating theatre.
Danish hospitals are adapting international protocols that let women click a button to deliver small intravenous doses, with lockout intervals typical of international PCIA practice. Some European units have used the method for over a decade, and available data from large series suggest low rates of serious maternal adverse events, though published case reports do document respiratory arrest and cardiorespiratory arrest associated with remifentanil in labour. According to Statistics Denmark birth register data, foreign-born mothers account for a substantial and growing share of births in Denmark, meaning a significant proportion of women potentially offered remifentanil are navigating childbirth outside their first language.
Off-label remifentanil use meets language barrier
Remifentanil’s European product licence covers anaesthesia and mechanically ventilated intensive care patients. It does not include a dedicated section on spontaneous-breathing obstetric patients. That makes labour use technically off-label in many jurisdictions, raising medico-legal questions if something goes wrong.
According to Danmarks Apotekerforening, the standard Danish medicines database lists remifentanil as suitable only for hospital use, with dosing individualised by age, weight, and organ function. It offers no labour-specific section, and Danish-language product information is the standard default, with English obstetric guidance limited. For the growing share of foreign-born mothers, that creates an informed-consent gap that women and clinicians often must address through verbal counselling alone.
Costs and monitoring for remifentanil in labour
A large Dutch multicentre randomised trial, the RAVEL study, compared patient-controlled remifentanil to epidural in 1,358 women. According to the RAVEL economic analysis, overall hospital costs averaged €2,900 per woman in the remifentanil group versus €3,185 for epidural. The mean difference of €282 was not statistically significant, and arose mainly from fewer neonatal admissions in the remifentanil group. The analysis concluded that remifentanil is not a cost-saving silver bullet.
The drug itself is relatively cheap. According to Danmarks Apotekerforening, a two-milligram vial of Remifentanil Fresenius Kabi costs approximately DKK 292 in Danish hospitals. However, the UK Summary of Product Characteristics states that remifentanil should only be used where facilities for monitoring and managing respiratory depression are immediately available. Clinical guidelines and professional recommendations specify that this means continuous pulse oximetry and oxygen on standby, with one-to-one midwife care as a further standard recommended by professional bodies, though this requirement appears in clinical guidance rather than in the product characteristics themselves. Staff safety protocols have not always kept pace with new drug rollouts on maternity wards.
What expat women can do
Foreign residents can request multilingual information at antenatal visits. They should ask whether remifentanil patient-controlled analgesia is available at their chosen hospital, what monitoring will be in place, and whether an anaesthesiologist will assess them. Women can also ask how often breathing and foetal heart rate will be checked, and whether free professional interpreters are offered during labour.
According to general Danish healthcare rights guidance, regions can provide interpreters when clinically indicated. Women should request this explicitly in their birth plan if Danish is not their first language. Remifentanil is an offer, not a requirement. Established alternatives such as epidural, nitrous oxide, or non-pharmacological techniques remain available. Hospital accessibility tools can help women flag communication needs ahead of labour.
A demographic reality
According to Statistics Denmark, foreign-born mothers account for a significant and growing share of all births in Denmark, a pattern that places the country alongside other European nations where migration has become a major factor in maternity service planning. The country’s high proportion of foreign-born mothers makes language access and culturally competent counselling especially important when introducing a potent opioid for labour pain. An adverse incident involving a poorly counselled patient could quickly turn a clinical innovation story into a political debate about healthcare equity and pharmaceutical risk communication.
Remifentanil’s migration from operating theatres onto labour wards is part of a broader European trend toward multimodal, patient-controlled analgesia. Short-acting agents are titrated by patients themselves to improve autonomy and offer flexible dosing. But that autonomy only works if the woman pressing the button understands what she is receiving. For now, Danish-language product information remains the standard default, and English-language obstetric guidance on remifentanil can be difficult to find. Healthcare professionals and foreign-born women alike often rely on verbal counselling to fill that gap.
